Skip to main content Skip to search Skip to main navigation

Swissmedic: Invalid Certification of the Notified Body ECM

On 9 January 2024, the Swiss Medicines Agency Swissmedic informed about critical deficits in the system of medical device regulation. 

To ensure safety and efficiency, medical devices and the quality management system of medical device manufacturers are inspected and continuously monitored by notified bodies. The German notified body ECM (ECM-Zertifizierungsgesellschaft für Medizinprodukte in

Europa GmbH, Aachen) used to be such a notified body until its designation expired on 25 May 2020 and has not been renewed by the corresponding German authority. Since then, ECM-certified products have no longer been monitored in accordance with the requirements of the Therapeutic Products Act.

Last year, Swissmedic discovered that ECM certified medical devices of foreign manufacturers were still being sold in Switzerland. In response, the Swiss authority informed the approximately 980 registered Swiss authorised representatives of foreign manufacturers about the problem in June 2023 and asked them to review their mandates.

During the period from July to October 2023, the Swiss authority then carried out extensive research for a sample check. This revealed that 7 of the 15 specifically selected authorised representatives had products with an ECM certificate in their portfolio.

Swissmedic has ordered the authorised representatives concerned to take corrective action to ensure that the products distributed in Switzerland comply with the regulatory requirements.


Source:

Swissmedic:  Announcements on market control issues

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next